Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Therapy Cells Inc.
Fiscal year is January-December. All values USD millions. 2008 2009 2012 2013 5-year trend
Sales/Revenue - 1.39M 0 10,164 0
Cost of Goods Sold (COGS) incl. D&A - 847,976 - - 439
COGS excluding D&A - 786,244 - - 0
Depreciation & Amortization Expense - 61,732 0 0 439
Depreciation - 61,732 - 0 439
Amortization of Intangibles - - - 0 0
Gross Income - 537,644 - - (439)
2008 2009 2012 2013 5-year trend
SG&A Expense - 1.63M - 130,070 94,439
Research & Development - 0 0 - 0
Other SG&A - 1.63M - 130,070 94,439
Other Operating Expense - 0 0 0 0
Unusual Expense - 0 0 0 0
EBIT after Unusual Expense - 0 0 0 0
Non Operating Income/Expense - 1,369 0 0 0
Non-Operating Interest Income - - - 0 0
Equity in Affiliates (Pretax) - - - - 0
Interest Expense - 103,715 - 5,586 1,375
Gross Interest Expense - 103,715 - 5,586 1,375
Interest Capitalized - 0 0 0 0
Pretax Income - (1.2M) 0 (125,492) (96,253)
Income Tax - (89,133) 0 0 0
Income Tax - Current Domestic - 3,353 - - -
Income Tax - Current Foreign - 0 - - -
Income Tax - Deferred Domestic - (13,814) - - -
Income Tax - Deferred Foreign - (78,672) - - -
Income Tax Credits - 0 - - -
Equity in Affiliates - 0 0 0 0
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income - (1.11M) 0 (125,492) (96,253)
Minority Interest Expense - 0 0 0 0
Net Income - (1.11M) 0 (125,492) (96,253)
Extraordinaries & Discontinued Operations - 0 (172,953) 0 0
Extra Items & Gain/Loss Sale Of Assets - 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations - 0 (172,953) 0 0
Net Income After Extraordinaries - (1.11M) (172,953) (125,492) (96,253)
Preferred Dividends - 0 0 0 0
Net Income Available to Common - (1.11M) 0 (125,492) (96,253)
EPS (Basic) - (128,571.43) (14,285.71) () ()
Basic Shares Outstanding - 9 8 77.3M 110.55M
EPS (Diluted) - (128,571.43) (14,285.71) () ()
Diluted Shares Outstanding - 9 8 77.3M 110.55M
EBITDA - (1.03M) 0 (119,906) (94,439)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.